

Current report 25/2020

July 27, 2020

Registration of the Rights to Series I Shares in the book-entry form by the National Depository for Securities

With reference to the current reports no. 22/2020 (dated 13 July 2020), no. 23/2020 (dated 15 July 2020) and no. 24/2020 (dated 22 July 2020) the Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Company") hereby announces that on 27 July 2020, the National Depository for Securities entered into an agreement with the Company regarding the registration of 2,384,245 rights to Series I Shares ("Rights to Shares"). The registration of Rights to Shares is conditioned upon admitting and introducing Rights to Shares to listing on the regulated market (main market) operated by the Warsaw Stock Exchange. The registration of Rights to Shares will take place within 3 days following receiving the decision on admitting and introducing Rights to Shares to trading on the regulated market.

Legal basis: Article 56.1.2 of the Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organised Trading and Public Companies, dated 29 July 2005

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board